Vaccine最新文献

{"title":"Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.","authors":"Juozas Grigas, Ugne Spancerniene, Martynas Simanavicius, Arnoldas Pautienius, Rolandas Stankevicius, Paulius Lukas Tamosiunas, Arunas Stankevicius","doi":"10.1016/j.vaccine.2024.126561","DOIUrl":"10.1016/j.vaccine.2024.126561","url":null,"abstract":"<p><p>Hepatitis E virus genotype 3 (HEV-3) is a zoonotic pathogen capable of infecting human, porcine, and other animal hosts. Despite a broad host range and abundance of species that act as reservoirs for human infections, no commercially available animal vaccines against HEV-3 are currently available. In the present study, we tested the capacity of recombinant aa 112-608 wild boar-derived HEV-3 capsid protein (rORF2p) to induce an immune response in immunized pigs. Four 6 week old pigs were administered 1 ml of 200 μg/ml rORF2p, followed by booster administration after 14 days. Blood samples were collected until 28 days after initial immunization. Dominant cell phenotypes and anti-HEV IgG concentrations were determined. A significant anti-HEV IgG, monocyte/macrophage, B cell and T cell response has been detected in immunized pigs. In turn, our findings suggest the capacity of rORF2p to elicit an immune response in pigs, suggesting the potential for its use as a vaccine candidate.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126561"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]\".","authors":"Chandini R MacIntyre, Zubair Akhtar, Aye Moa","doi":"10.1016/j.vaccine.2024.126486","DOIUrl":"10.1016/j.vaccine.2024.126486","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126486"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.","authors":"Pierre-Philippe Piché-Renaud, Samantha S M Drover, Peter C Austin, Shaun K Morris, Sarah A Buchan, Sharifa Nasreen, Kevin L Schwartz, Mina Tadrous, Nisha Thampi, Sarah E Wilson, Kumanan Wilson, Astrid Guttmann, Jeffrey C Kwong","doi":"10.1016/j.vaccine.2024.126539","DOIUrl":"10.1016/j.vaccine.2024.126539","url":null,"abstract":"<p><strong>Background: </strong>Understanding how the efficacy of COVID-19 vaccines translates from clinical trials to real-world settings is critical to inform evolving vaccination policies. The objective of this study was to assess COVID-19 vaccine effectiveness (VE) against severe COVID-19-related outcomes in children aged 5-11 years, including COVID-19-related hospital admissions and multisystem inflammatory syndrome in children (MIS-C).</p><p><strong>Methods: </strong>We conducted a retrospective, population-based cohort study using linked health administrative data in the first year following the emergence of the Omicron variant (January 2 to December 31, 2022) in Ontario, Canada. Baseline differences between subgroups of interest were compared using standardized differences. We used multivariable Cox proportional hazard regression models to estimate VE by time since last vaccine dose by treating vaccination as a time-varying exposure, compared to unvaccinated children.</p><p><strong>Results: </strong>We included a total of 1,058,740 children, of which 583,867 (55.1 %) had received at least one vaccine dose by the end of the study period. In total, there were 185 COVID-19-related hospital admissions and 39 cases of MIS-C. The rate of COVID-19-related admission was substantially higher in children with an underlying comorbid condition compared to children who were previously healthy (adjusted hazard ratio [aHR] = 4.77, 95 %CI, 3.56-6.38). VE against COVID-19-related admission ranged from 93 % (95 %CI, 52-99 %) 7-29 days after a second dose to 63 % (95 %CI; 41-77 %) ≥120 days after a second dose. There was no statistically significant difference in the rate of MIS-C in children who received at least one dose of the vaccine compared to unvaccinated children (aHR = 0.71; 95 %CI, 0.38-1.34).</p><p><strong>Conclusions: </strong>We found that, for children aged 5-11 years, VE against COVID-19-related hospitalization was high in the first four months after a second dose. Children with comorbid conditions were found to be at much higher risk of COVID-19-related severe outcomes and thus may benefit most from COVID-19 vaccination.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126539"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe Institute for Advanced Study conference proceedings.","authors":"Elissa R Weitzman, Margarita Alegria, Arthur Caplan, David Dowling, Jay Evans, Carl Erik Fisher, Ayana Jordan, Joe Kossowsky, Misia Landau, Heidi Larson, Ofer Levy, Sharon Levy, Seth Mnookin, Sharon Reif, Jennifer Ross, Amy Caryn Sherman","doi":"10.1016/j.vaccine.2024.126324","DOIUrl":"10.1016/j.vaccine.2024.126324","url":null,"abstract":"<p><p>Despite significant public health attention and investment, hundreds of thousands of individuals have suffered fatal opioid overdose since the onset of the opioid crisis. Risk of opioid overdose has been exacerbated by the influx of fentanyl, a powerful synthetic opioid, into the drug supply. The National Institutes of Health Helping End Addiction Long-term (HEAL) Initiative is supporting the development of vaccines targeting fentanyl to protect against overdose. If successful, a vaccine would induce anti-fentanyl antibodies to sequester fentanyl (but not other opioids) in the blood, preventing fentanyl from crossing into the brain and reaching the central nervous system where it can cause overdose. Introduction of an overdose preventing strategy that relies on a vaccine to confer passive protection may be impactful. However, vaccines are poorly understood by the public and politicized. Moreover, the overdose ecosystem is complex and extends across numerous social, economic, medical, and cultural systems. As such, optimal use of a vaccine strategy to address overdose may benefit from multidisciplinary consideration of the social, ethical, and systemic factors that influence substance use and overdose that may also impact the acceptability of a fentanyl vaccine and related implementation strategies. In March 2022, Dr. Elissa Weitzman convened a two-day conference at the Harvard Radcliffe Institute for Advanced Study on the Social Complexity of a Fentanyl Vaccine to Prevent Opioid Overdose. In all, 19 professionals from diverse disciplines (medicine, psychology, history, ethics, immunology, vaccinology, communications, policy) attended the conference and led discussions that centered on population health and epidemiology, history of medicine and frameworks for understanding substance use, ethics, decision-making and attitudes, and operational issues to the question of a novel immunotherapy targeting fentanyl overdose. Participants also debated the risks and benefits of vaccine administration in response to fictional clinical case vignettes. A summary of the conference presentations and discussions follows.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126324"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases\" [Vaccine 42 (12) (2024) 3039-3048].","authors":"Anna Schultze, Ivonne Martin, Davide Messina, Sophie Bots, Svetlana Belitser, Juan José Carreras-Martínez, Elisa Correcher-Martinez, Arantxa Urchueguía-Fornes, Mar Martín-Pérez, Patricia García-Poza, Felipe Villalobos, Meritxell Pallejà-Millán, Carlo Alberto Bissacco, Elena Segundo, Patrick Souverein, Fabio Riefolo, Carlos E Durán, Rosa Gini, Miriam Sturkenboom, Olaf Klungel, Ian Douglas","doi":"10.1016/j.vaccine.2024.126438","DOIUrl":"10.1016/j.vaccine.2024.126438","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126438"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in parental reasons for lack of intent to initiate HPV vaccination among adolescents ages 13-17 years: National Immunization Survey - Teen 2019-2021.","authors":"Erika Escabí-Wojna, Paola M Alvelo-Fernández, Erick Suárez, Vivian Colón-López","doi":"10.1016/j.vaccine.2024.126584","DOIUrl":"10.1016/j.vaccine.2024.126584","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate parents' main reasons for lack of intent to vaccinate their adolescent against human papillomavirus (HPV) from 2019 to 2021 and to examine changes in these main reasons stratified by sex of the adolescent.</p><p><strong>Methods: </strong>NIS-Teen data from 2019 to 2021 were used. Parents who had not vaccinated their adolescent aged 13-17 against HPV and had no intent to do so in the next 12 months were asked the main reason behind this decision. Reasons were grouped into eight domains. A multinomial logistic regression model stratified by sex was used to assess changes in the likelihood of each domain for 2020 and 2021 in comparison to 2019.</p><p><strong>Results: </strong>A significant interaction between the reasons for lack of intent to vaccinate against HPV and year by sex was documented (p < 0.001). For males, the odds of parents reporting vaccine misinformation (ORadj: 1.30, 95 % CI: 1.26, 1.35), safety and effectiveness concerns (ORadj: 1.08, 95 % CI: 1.05, 1.12), systemic barriers (ORadj: 2.57, 95 % CI: 2.48, 2.66), lack of knowledge (ORadj: 1.44, 95 % CI: 1.39, 1.49), sociocultural barriers (ORadj: 3.20, 95 % CI: 3.09, 3.32), already UTD (ORadj: 2.48, 95 % CI: 2.39, 2.56), and handicapped/special needs/illness (ORadj: 1.88, 95 % CI: 1.79, 1.97), were significantly higher in 2021 compared to 2019. Whereas for females, the odds of reporting all domains were significantly lower in 2021 compared to 2019.</p><p><strong>Conclusion: </strong>The main domain reported was vaccine misinformation. Parents of males were more likely to report all domains in 2021 compared to 2019, the inverse of females. These can be addressed through public health interventions such as launching media campaigns to combat vaccine misinformation tailored to parents of male adolescents.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126584"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children.","authors":"Denise Anabe, Johanna T Teräsjärvi, Alex-Mikael Barkoff, Aapo Knuutila, Bernd Pape, Pieter van Gageldonk, Annemarie Buisman, Jussi Mertsola, Qiushui He","doi":"10.1016/j.vaccine.2024.126573","DOIUrl":"10.1016/j.vaccine.2024.126573","url":null,"abstract":"<p><strong>Background: </strong>Despite extensive vaccinations, pertussis remains endemic and epidemic in multiple countries. The persistence of cases can be partly attributed to the significant individual variation in vaccine responses. This study evaluated the association of baseline cytokines (before booster vaccination) on antibody concentrations to Tdap-vaccine antigens.</p><p><strong>Methods: </strong>Healthy Finnish children (7-10y, n = 36), adolescents (11-15y, n = 37), young adults (20-34y, n = 25), and older adults (60-70y, n = 23) received a Tdap3-IPV booster. Serum antibodies against pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (Prn), fimbriae 2/3, diphtheria toxoid (DT), and tetanus toxoid (TT), as well as PT neutralizing antibodies were measured before, one month, and one year after the booster. Baseline serum concentrations of IFN-γ, IL-2, IL-5, IL-10, IL-13, IL-17 A and IL-17F were determined.</p><p><strong>Results: </strong>The proportion of detectable and undetectable baseline cytokines varied between age groups 58.3 % of children had a higher proportion of detectable IL-5, IL-10, IL-13, and IL-17F compared to adolescents (IL-5, 37.8 %; IL-10, 48.6 %; IL-13, 48.6 %; IL-17F, 37.7 %), young adults (IL-5, 36.0 %; IL-10, 28.0 %; IL-13, 36.0 %; IL-17F, 44.0 %), and older adults (IL-5, 26.1 %; IL-10, 21.7 %; IL-13, 39.1 %; IL-17F, 30.4 %). IFN-γ had a lower detectability in children (44.4 %) and young (40.0 %) and older adults (39.1 %) in contrast to adolescents (62.2 %). IL-2 was undetectable in all age groups while the proportion of detectable IL-17 A decreased with age. A mixed model showed that undetectable baseline levels of IFN-γ, IL-2, IL-10, and IL-17 A were associated with higher antibody concentrations in children before and after vaccination, particularly against PT. Positive associations were observed in adolescents for anti-TT concentrations and young adults for anti-FHA IgA concentrations.</p><p><strong>Conclusion: </strong>These findings indicate a possible role of existing cytokines in pertussis booster antibody concentrations in children and warrant further studies in different populations. However, the results should be interpreted with caution as the number of subjects is limited.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126573"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142776171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using human papillomavirus (HPV) vaccine in controlled temperature chain (CTC): A solution looking for a problem? Or a solution to problems that are not systematically documented?","authors":"Dijana Spasenoska, Paul Bloem, Hiroki Akaba, Anna-Lea Kahn","doi":"10.1016/j.vaccine.2024.126399","DOIUrl":"10.1016/j.vaccine.2024.126399","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126399"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.","authors":"Paul D Kasaija, Fredrick Kabi, Jimmy Semakula, Ivan Kyakuwa, Marinela Contreras, Gabriela de la Fuente, Justus Rutaisire, Swidiq Mugerwa, Christian Gortázar, José de la Fuente","doi":"10.1016/j.vaccine.2024.126562","DOIUrl":"10.1016/j.vaccine.2024.126562","url":null,"abstract":"<p><p>After approval of the Subolesin-based anti-tick vaccine in Uganda, we completed a one-year follow-up evaluation study. The results showed significantly 2.1-5.0-fold higher anti-SUB IgG antibody titers in vaccinated cattle in Mbarara and Maruzi with vaccine effectiveness higher than 95 %. In Mbarara, total number of ticks were 0.8-fold lower in vaccinated cattle with a negative correlation tendency between anti-SUB antibody titers and tick counts. The CCHFV-seropositive cattle significantly decreased in 40 % in SUB-vaccinated animals with a significant positive correlation between CCHFV-seropositive cattle and the total number of ticks per animal and a negative correlation tendency between anti-SUB antibody titers and CCHFV-seropositive cattle. A boosting vaccine dose yearly after primary vaccination with three doses is sufficient to maintain protective antibody titers against ticks and tick-borne diseases affecting human and animal health. These results are relevant for implementation of anti-tick Subolesin-based vaccines in Uganda and other countries in Sub-Saharan Africa.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"44 ","pages":"126562"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received\" [Vaccine 42 (22) (2024) 126025].","authors":"Paskorn Sritipsukho, Pakatip Sinlapamongkolkul, Araya Satdhabudha, Chanapai Chaiyakulsil, Surakameth Mahasirimongkol, Waritta Sawaengdee, Waraphorn Fukpho, Thana Khawcharoenporn","doi":"10.1016/j.vaccine.2024.126403","DOIUrl":"10.1016/j.vaccine.2024.126403","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":" ","pages":"126403"},"PeriodicalIF":0.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}